Coppell Advisory Solutions Corp. Invests $414,000 in Stryker Co. (NYSE:SYK)

Coppell Advisory Solutions Corp. bought a new stake in Stryker Co. (NYSE:SYK) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,157 shares of the medical technology company’s stock, valued at approximately $414,000.

A number of other large investors have also added to or reduced their stakes in SYK. Harbor Investment Advisory LLC raised its stake in shares of Stryker by 0.4% during the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock valued at $2,499,000 after acquiring an additional 31 shares in the last quarter. Aspen Investment Management Inc lifted its stake in shares of Stryker by 0.7% during the 1st quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock worth $1,563,000 after purchasing an additional 31 shares during the last quarter. Proficio Capital Partners LLC boosted its position in Stryker by 2.4% during the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock valued at $507,000 after purchasing an additional 33 shares in the last quarter. Consolidated Portfolio Review Corp grew its stake in Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares during the last quarter. Finally, FourThought Financial Partners LLC raised its stake in shares of Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after acquiring an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.9 %

Shares of SYK traded up $2.82 during mid-day trading on Thursday, reaching $330.27. The stock had a trading volume of 714,437 shares, compared to its average volume of 1,313,084. The business’s fifty day moving average is $338.89 and its 200 day moving average is $339.52. The firm has a market cap of $125.82 billion, a price-to-earnings ratio of 37.84, a P/E/G ratio of 2.60 and a beta of 0.89. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 23.26% and a net margin of 16.12%. The company’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.54 earnings per share. On average, sell-side analysts predict that Stryker Co. will post 11.95 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. The ex-dividend date was Friday, June 28th. Stryker’s payout ratio is 36.53%.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Roth Mkm increased their price objective on Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Stifel Nicolaus dropped their price target on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research note on Wednesday. Citigroup increased their price objective on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Barclays boosted their target price on shares of Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Finally, Truist Financial decreased their target price on Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a report on Thursday. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $371.74.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.